

CANADIAN GUIDELINES ON SEXUALLY TRANSMITTED INFECTIONS (2008 UPDATE)

V – MANAGEMENT AND TREATMENT OF SPECIFIC INFECTIONS

GENITAL HERPES SIMPLEX VIRUS (HSV) INFECTIONS (January 2008)

References

1. Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: clinical manifestations, course, and complications. *Ann Intern Med* 1983;98:958–972.
2. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. *J Infect Dis* 2002;186(suppl 1):S3–28.
3. Armstrong GL, Schillinger J, Markowitz L, et al. Incidence of herpes simplex virus type 2 infection in the United States. *Am J Epidemiol* 2001;153:912–920.
4. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. *N Engl J Med* 1997;337:1105–1111.
5. Patrick DM, Dawar M, Cook DA, Krajden M, Ng HC, Rekart ML. Antenatal seroprevalence of Herpes simplex virus type 2 (HSV-2) in Canadian women: HSV-2 prevalence increases throughout the reproductive years. *Sex Transm Dis* 2001;28:424–428.
6. Singh AE, Romanowski B, Wong T, et al. Herpes simplex virus seroprevalence and risk factors in 2 Canadian sexually transmitted disease clinics. *Sex Transm Dis* 2005;32:95–100.
7. Lafferty WE, Downey L, Celum C, Wald A. Herpes simplex virus type 1 as a cause of genital herpes: impact surveillance and prevention. *J Infect Dis* 2000;181:1454–1457.
8. Nilsen A, Myrmet H. Changing trends in genital herpes simplex virus infection in Bergen, Norway. *Acta Obstet Gynecol Scand* 2000;79:693–696.
9. Forward KR, Lee SHS. Predominance of herpes simplex virus type 1 from patients with genital herpes in Nova Scotia. *Can J Infect Dis* 2003;14:94–96.
10. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. *N Engl J Med* 2004;350:11–20.
11. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. *Ann Intern Med* 1992;116:197–202.
12. Bryson Y, Dillon M, Bernstein DI, Radolf J, Zakowski P, Garratty E. Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. *J Infect Dis* 1993;167:942–946.
13. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. *N Engl J Med* 1999;341:432–438.
14. Corey L, Fife KH, Benedetti JK, et al. Intravenous acyclovir for the treatment of primary genital herpes. *Ann Intern Med* 1983;98:914–921.
15. Sacks SL. *The Truth about Herpes*. 4th ed. Vancouver, BC: Gordon Soules Book Publishers: 1997.
16. Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. *N Engl J Med* 1987;316:1444–1449.
17. Benedetti JK, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. *Ann Intern Med* 1999;131:14–20.

18. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex type 2 infection in asymptomatic seropositive persons. *N Engl J Med* 2000;342:844–850.
19. Wald A, Zeh J, Selke S, Warren T, Ashley R, Corey L. Genital shedding of herpes simplex virus among men. *J Infect Dis* 2002;186(suppl 1):S34–S39.
20. Wald A, Zeh J, Selke S, Ashley R, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. *N Engl J Med* 1995;333:770–775.
21. Cowan FM, Copas A, Johnson AM, Ashley R, Corey L, Mindel A. Herpes simplex virus type 1 infection: a sexually transmitted infection of adolescence? *Sex Transm Infect* 2002;78:346–348.
22. Wald AM, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. *JAMA* 2001;285:3100–3106.
23. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. *N Engl J Med* 2002;347:1652–1661.
24. Ashley-Morrow R, Krantz E, Wald A. Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2. *Sex Transm Dis* 2003;30:310–314.
25. Corey L, Holmes KK. Genital herpes simplex virus infections: current concepts in diagnosis, therapy and prevention. *Ann Intern Med* 1983;98:973–983.
26. Wald A, Huang M-L, Carrell D, Selke S, Corey L. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. *J Infect Dis* 2003;188:1345–1351.
27. Solomon AR, Rasmussen JE, Varani J, Pierson CL. The Tzanck smear in the diagnosis of cutaneous herpes simplex. *JAMA* 1984;251:633–635.
28. Kohl S, Adam E, Matson DO, Kaufman RH, Dreesman GR. Kinetics of human antibody responses to primary genital herpes simplex virus infection. *Intervirology* 1982;18:164–168.
29. Lopez C, Arvin AM, Ashley R. Immunity to herpesvirus infections in humans. In: Roizman B, Whitley RJ, Lopez C, eds. *The Human Herpesviruses*. New York, NY: Raven Press; 1993.
30. Ashley RL, Eagleton M, Pfeiffer N. Ability of a rapid serology test to detect seroconversion to herpes simplex virus type 2 glycoprotein G soon after infection. *J Clin Microbiol* 1999;37:1632–1633.
31. Ashley RL. Progress and pitfalls in serological testing for genital herpes. *Herpes* 1994;1:49–51.
32. Diamond C, Selke S, Ashley R, Benedetti J, Corey L. Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease. *Sex Transm Dis* 1999;26:221–225.
33. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. *MMWR Recomm Rep* 2002;51(RR-6):1–78.
34. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. *J Infect Dis* 2002;185:45–52.
35. Aoki FY. Contemporary antiviral drug regimens for the prevention and treatment of orolabial and anogenital herpes simplex virus infection in the normal host: four approved indications and 13 off-label uses. *Can J Infect Dis*. 2003;14:17–27.
36. Corey L, Benedetti J, Critchlow CW, et al. Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy. *J Antimicrob Chemother* 1983;12(suppl B):79–88.
37. Mertz GJ, Critchlow CW, Benedetti J, et al. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. *JAMA* 1984;252:1147–1151.
38. Murphy SM, Ruck F, Kitchin VS. Oral famciclovir (FCV) a new antiherpes agent: comparative study with acyclovir in clinic initiated treatment of first episode genital herpes (FGH) [abstract]. Presented at: European Academy of Dermatology and Venereology/Triaena Congress. 1991; Athens, Greece.

39. Loveless M, Harris JRW, Sacks SL. Famciclovir in the management of first-episode genital herpes. *Infect Dis Clin Pract* 1997;6(suppl 1):S12–S16.
40. Fife KH, Barbarash RA, Rudolph T, Degregorio B, Roth R. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. *Sex Transm Dis* 1997;24:481–486.
41. Spruance SL, Tyring SK, DeGregorio B, Miller C, Beutner K. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. *Arch Intern Med* 1996;156:1729–1735.
42. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind, multicenter trial. Canadian Famciclovir Study Group. *JAMA* 1996;276:44–49.
43. Tyring SK, Douglas JM Jr, Corey L, Spruance SL, Esmann J. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valacyclovir International Study Group. *Arch Dermatol* 1998;134:185–191.
44. Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. *Clin Infect Dis* 2002;34:944–948.
45. Romanowski B, Marina RB, Roberts JN, Valtrex HS230017 Study Group. Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. *Sex Transm Dis* 2003;30:226–231.
46. Patel R, Tyring S, Strand A, Price MJ, Grant DM. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. *Sex Transm Infect* 1999;75:398–402.
47. Sacks SL, Fox R, Levendusky P, et al. Chronic suppression for six months compared with intermittent lesional therapy of recurrent genital herpes using oral acyclovir: effects on lesions and nonlesional prodromes. *Sex Transm Dis* 1988;15:58–62.
48. Thin RN, Jeffries DJ, Taylor PK, et al. Recurrent genital herpes suppressed by oral acyclovir: a multicentre double blind trial. *J Antimicrob Chemother* 1985;16:219–226.
49. Mindel A, Weller IV, Faherty A, et al. Prophylactic oral acyclovir in recurrent genital herpes. *Lancet* 1984;2:57–59.
50. Kinghorn GR, Jeavons M, Rowland M, et al. Acyclovir prophylaxis of recurrent genital herpes: randomized placebo controlled crossover study. *Genitourin Med* 1985;61:387–390.
51. Halsos AM, Salo AP, Lassus A, et al. Oral acyclovir suppression of recurrent genital herpes: a double-blind, placebo-controlled, crossover study. *Acta Derm Venereol* 1985;65:59–63.
52. Blom I, BŠck O, Egelrud T, et al. Long-term oral acyclovir treatment prevents recurrent genital herpes. *Dermatologica* 1986;173:220–223.
53. Mertz GJ, Jones CC, Mills J, et al. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. *JAMA* 1988;260:201–206.
54. Baker DA, Blythe JG, Kaufman R, Hale R, Portnoy J. One-year suppression of frequent recurrences of genital herpes with oral acyclovir. *Obstet Gynecol* 1989;73:84–87.
55. Kroon S, Petersen CS, Andersen LP, Rasmussen LP, Vestergaard BF. Oral acyclovir suppressive therapy in severe recurrent genital herpes. A double-blind, placebo-controlled cross-over study. *Dan Med Bull* 1989;36:298–300.
56. Mostow SR, Mayfield JL, Marr JJ, Drucker JL. Suppression of recurrent genital herpes by single daily dosages of acyclovir. *Am J Med* 1988;85(2A):30–33.
57. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. *J Infect Dis* 1998;178:603–610.

58. Douglas JM, Critchlow C, Benedetti J, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. *N Engl J Med* 1984;310:1551–1556.
59. Strauss SE, Takiff HE, Seidlin M, et al. Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. *N Engl J Med* 1984;310:1545–1550.
60. Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. *Arch Intern Med* 1997;157:343–349.
61. Diaz-Mitoma F, Sibbald GR, Shafran SD, Boon R, Saltzman RL. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. *JAMA* 1998;280:887–892.
62. Patel R, Bodworth NJ, Woolley P, et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group. *Genitourin Med* 1997;73:105–109.
63. Stray-Pedersen B. Acyclovir in late pregnancy to prevent neonatal herpes simplex. *Lancet* 1990;336:756.
64. Braig S, Luton D, and Sibony O, et al. Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding. *Eur J Obstet Gynecol Reprod Biol* 2001;96:55–58.
65. Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD Jr. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. *Obstet Gynecol* 1996;87:69–73.
66. Watts DH, Brown ZA, Money D, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and caesarean delivery. *Am J Obstet Gynecol* 2003;188:836–843.
67. Sheffield JS, Hill JB, Mollier LM, Laibl VR, Roberts SW, Schez PJ and Wendel Jr. GD. Valacyclovir prophylaxis to prevent herpes at delivery. *Am J Obstet Gynecol* 2006; 180:141-147
68. Reiff-Eldridge R, Heffner CR, Ephrons SA. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. *Am J Obstet Gynecol* 2000; 182:159-163
69. Kimberlin DW, Lin CY, Jacobs RF, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. *Pediatrics* 2001;108:230–238.
70. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. *JAMA* 2003;289:203–209.
71. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. *N Engl J Med* 1997;337:509–515.
72. Kropp RY, Wong T, Cormier L, Ringrose A, Embree J, Steben M, Canadian Paediatric Surveillance Program (CPSP). Epidemiology of neonatal herpes simplex virus infections in Canada. Presented at the International Society for STD Research (ISSTD) conference 2005, Amsterdam.
73. Whitley RJ, Corey L, Arvin A, et al. Changing presentation of herpes simplex virus infection in neonates. *J Infect Dis* 1988;158:109–116.
74. Kimberlin DW, Lin CY, Jacobs RF, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. *Pediatrics* 2001;108:223–229.
75. Enright AM, Prober CG. Neonatal herpes infection: diagnosis, treatment and prevention. *Semin Neonatol* 2002;7:283–291.
76. Koskiniemi M, Happonen JM, Jarvenpaa AL, Pettay O, Vaheri A. Neonatal herpes simplex virus infection: a report of 43 patients. *Pediatr Infect Dis* 1989;8:30–35.
77. Prober CG, Sullender WM, Yasukawa LL, Au DS, Yeager AS, Arvin AM. Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections. *N Engl J Med* 1987;316:240–244.